These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8245876)

  • 1. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study.
    Legendre C; Ducloux D; Ferroni A; Chkoff N; Geffrier C; Rouzioux C; Kreis H
    J Med Virol; 1993; Suppl 1():118-22. PubMed ID: 8245876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ; Wirin D; Shaked A; Busuttil RW
    Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
    Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
    Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
    Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
    Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
    Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients.
    Kletzmayr J; Kotzmann H; Popow-Kraupp T; Kovarik J; Klauser R
    J Am Soc Nephrol; 1996 Feb; 7(2):325-30. PubMed ID: 8785404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients.
    Rostaing L; Crespin A; Icart J; Lloveras JJ; Durand D; Martinet O; Didier J
    Transpl Int; 1994; 7 Suppl 1():S331-5. PubMed ID: 11271244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
    Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
    Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients.
    Martin M; Mañez R; Linden P; Estores D; Torre-Cisneros J; Kusne S; Ondick L; Ptachcinski R; Irish W; Kisor D
    Transplantation; 1994 Oct; 58(7):779-85. PubMed ID: 7940710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients.
    Mollison LC; Richards MJ; Johnson PD; Hayes K; Munckhof WJ; Jones RM; Dabkowski PD; Angus PW
    J Infect Dis; 1993 Sep; 168(3):721-4. PubMed ID: 8394862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S; Ynares C; Dummer S; Helderman JH
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus disease after heart transplantation: is acyclovir prophylaxis indicated?
    Elkins CC; Frist WH; Dummer JS; Stewart JR; Merrill WH; Carden KA; Bender HW
    Ann Thorac Surg; 1993 Dec; 56(6):1267-72; discussion 1272-3. PubMed ID: 8267423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients.
    Gavaldà J; de Otero J; Murio E; Vargas V; Rosselló J; Calicó I; Margarit C; Pahissa A
    Transpl Int; 1997; 10(6):462-5. PubMed ID: 9428121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.